Smith & Nephew completes acquisition of optical tracking technology innovator Atracsys Sàrl (press release)
Smith & Nephew plc (LSE:SN, NYSE:SNN), the global medical technology business, today announces it has completed the acquisition of Atracsys Sàrl, the Switzerland-based provider of optical tracking technology used in computer-assisted surgery. The acquisition supports Smith & Nephew’s long-term commitment to develop its multi-asset digital surgery and robotics ecosystem to empower surgeons and improve clinical outcomes.
Atracsys’ fusionTrack 500 optical tracking camera will be a core enabling technology for Smith & Nephew’s next-generation robotics platform, due for commercial release in 2020. The fusionTrack 500 offers superior measurement speed and latency performance, supporting reduced procedure times, as well as increased accuracy resulting in finer precision surgical tasks, such as bone cuts, compared to existing tracking technology.
The commercial terms of the acquisition have not been disclosed.
ENDS
Enquiries
Investors
Andrew Swift +44 (0) 1923 477433
Smith & Nephew
Media
Charles Reynolds +44 (0) 1923 477314
Smith & Nephew
Charis Gresser/Ayesha Bharmal +44 (0) 207 404 5959
Brunswick
About Smith & Nephew
Smith & Nephew is a portfolio medical technology business that exists to restore people’s bodies, and their self-belief. Smith & Nephew has leadership positions in Orthopaedics, Advanced Wound Management and Sports Medicine, more than 16,000 employees and a presence in more than 100 countries. Annual sales in 2018 were $4.9 billion. Smith & Nephew is a member of the FTSE100 (LSE:SN, NYSE:SNN). For more information about Smith & Nephew, please visit our corporate website www.smith-nephew.com and follow us on Twitter, LinkedIn or Facebook.